Two months after gaining the additional indication in the EU, Boehringer Ingelheim GmbH/Eli Lilly and Company’s Jardiance (empagliflozin) has been approved in the US for use in adult heart failure patients with reduced ejection fraction (HFrEF), where it will compete in a sector occupied by products such as AstraZeneca PLC’s Farxiga (dapagliflozin) and Novartis AG’s Entresto (sacubitril/valsartan).
And further details of empagliflozin’s potential benefits in a second group of heart failure patients, those with preserved ejection fraction...






